Xinhua Silk Road: Inheriting traditions while promoting innovation, Chinese pharmaceutical company contributes to TCM globalization

November 19, 2024 11:29 PM AEDT | By Cision
Follow us on Google News: https://kalkinemedia.com/resources/assets/public/images/google-news.webp

BEIJING, Nov. 19, 2024 /PRNewswire/ -- With continuous advancement of the Belt and Road Initiative, Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd. has been actively promoting the globalization of traditional Chinese medicine (TCM) through both inheriting traditional assets and engaging in modern innovations.

The company, based in southeast China's Fujian Province, has been making continuing efforts in recent years to improve the influence of TCM in Southeast Asia, Europe and other regions, as well as to increase international recognition of TCM through deepened international exchanges and cooperation.

Striving to expand its overseas market, the company has also visited Brazil, Argentina and other countries to inspect the market environment. The company was announced as one of the favorite Chinese brands among foreigners during this year's China Brand Day events.

The core product of the company, Pien Tze Huang, is listed as a national protected variety of TCM, with its traditional production techniques included as a national intangible cultural heritage and its export volume ranking among the top for many years amidst single varieties of Chinese patent medicine.

In old times, Pien Tze Huang used to be brought by the merchant teams from Zhangzhou to all around the world through the ancient Maritime Silk Road. Nowadays, the product is sold to a number of countries and regions including Singapore, Thailand, Indonesia, Malaysia, Canada and so on.

In order to meet the requirements of TCM globalization in the new era, the Chinese pharmaceutical company has continuously strengthened its scientific research capabilities in recent years, carrying out more than 30 original and integrated innovation studies in cooperation with research institutions.

In March this year, the China Association of Chinese Medicine announced that the revealing of the clinical efficacy mechanism of Pien Tze Huang had been selected as one of the top ten academic advances in the field of TCM in 2023, which is greatly conducive to improving international recognition of the product.

In the future, the company is committed to spreading the culture of TCM, opening up a broader global market, and continuing to contribute the wisdom of ancient Chinese medicine to the health of people around the world.

Original link: https://en.imsilkroad.com/p/343190.html

 


Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media Pty Ltd (“Kalkine Media, we or us”), ACN 629 651 672 and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content.
Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures displayed/music used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have made reasonable efforts to accredit the source wherever it was indicated as or found to be necessary.

This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.

Two ASX Listed Stocks Giving Bullish Indications

Recent Articles

Investing Tips

Previous Next
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.